SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31

Spero Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$1.12+0.02 (+1.82%)

Close on Oct 19, 2026

Community

Notes and questions about Spero Therapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Spero Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SPRO.

Revenue growth-3.3% · median 19.6%

Operating margin12.8% · median -282.5%

Net margin15.7% · median -232.5%

Advertisement
300 × 250